相关实验视频
Updated: Jul 5, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.2K
对低风险住院患者的积极性青素过敏取消标签计划的资源利用和成本评估
Derek Lanoue1, Adhora Mir2, Carl van Walraven2,3
1Division of Clinical Immunology and Allergy, McGill University, 1650 Cedar Ave., H3G1A4, Montreal, QC, Canada.
概括
一个主动的青素过敏取消标签的程序安全有效地识别低风险的住院患者的阿莫西林挑战. 这种方法简化了过敏评估,并增加了获得青素过敏取消标签的机会.
科学领域:
- 临床医学 临床医学
- 过敏和免疫学 过敏和免疫学
- 卫生经济学 卫生经济学
背景情况:
- 青素过敏评估和取消标签往往受到资源限制和住院医疗机构的高成本的阻碍.
- 需要积极的战略来提高青素过敏评估的效率.
研究的目的:
- 评估一项针对住院患者的积极性青素过敏脱标计划的安全性和可行性.
- 对干预措施的成本效益进行探索性经济分析.
主要方法:
- 一项试点干预涉及针对新入院患者的积极性青素过敏取消标签计划.
- 患有低风险青素过敏史的患者接受了250毫克口服阿莫西西林的挑战和1小时的观察.
- 通过使用各种医疗保健专业工资进行了经济评估.
主要成果:
- 在126名查的住院患者中,55人被评估,19人完成了口头挑战,导致12名患者被取消标签.
- 查所需的数字是4,评估所需的数字是1.8,以取消一个患者的标签.
- 年度实施成本从21,476美元 (药房技术员) 到61,121美元 (护士执业生/医生助理) 之间,每个患者的取消标签成本在53.29美元至151.67美元之间.
结论:
- 针对患有青素过敏的低风险住院患者,采用直接口服挑战的主动方法是安全和可行的.
- 这个模型可以在其他加拿大机构中复制,以提高青素过敏评估的准入.
相关概念视频
Pharmacovigilance
835
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
835
Allergic Drug Reactions
845
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
845
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
299
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
299
Allergic Reactions
27.4K
Overview
27.4K
Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445

